FitzPatrick Margaret M 4

What Happened
Margaret M. FitzPatrick, a director of AN2 Therapeutics, was granted 20,400 derivative shares (reported as an "A" award) on February 20, 2026. The filing shows an acquisition price of $0.00 (i.e., no cash paid at grant) and lists the instrument as a derivative. A footnote states these "option shares" shall vest on February 20, 2027, contingent on continuous service through that date. This is a grant/compensation event rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-02-20; Form 4 filed: 2026-02-23 (timely filing).
• Transaction type/code: A (Grant/Award of derivative securities).
• Quantity: 20,400 derivative shares; reported price: $0.00; reported total value: $0 (derivative award).
• Vesting: Footnote F1 — option shares vest on 2027-02-20 subject to continuous service.
• Shares owned after transaction: Not disclosed in this Form 4.
• Filing timeliness: Filed within the required reporting window (not marked late).

Context: This was a compensatory option award that vests in one year — it does not represent an immediate market purchase or sale. Such grants are common for directors and employees as compensation and do not, by themselves, indicate a buy/sell signal.